Journal List > Korean J Physiol Pharmacol > v.15(2) > 1025727

Kim, Lee, Kang, Lee, Jeong, Lee, Kim, Johnson, and Chun: Suppression of Autophagy and Activation of Glycogen Synthase Kinase 3beta Facilitate the Aggregate Formation of Tau

Abstract

Neurofibrillary tangle (NFT) is a characteristic hallmark of Alzheimer's disease. GSK3β has been reported to play a major role in the NFT formation of tau. Dysfunction of autophagy might facilitate the aggregate formation of tau. The present study examined the role of GSK3β-mediated phosphorylation of tau species on their autophagic degradation. We transfected wild type tau (T4), caspase-3-cleaved tau at Asp421 (T4C3), or pseudophosphorylated tau at Ser396/Ser404 (T4–2EC) in the presence of active or enzyme-inactive GSK3β. Trehalose and 3-methyladenine (3-MA) were used to enhance or inhibit autophagic activity, respectively. All tau species showed increased accumulation with 3-MA treatment whereas reduced with trehalose, indicating that tau undergoes autophagic degradation. However, T4C3 and T4-2EC showed abundant formation of oligomers than T4. Active GSK3β in the presence of 3-MA resulted in significantly increased formation of insoluble tau aggregates. These results indicate that GSK3β-mediated phosphorylation and compromised autophagic activity significantly contribute to tau aggregation.

References

1. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA. 1986; 83:4913–4917.
crossref
2. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. 2004; 29:95–102.
crossref
3. Lovestone S, Hartley CL, Pearce J, Anderton BH. Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules. Neuroscience. 1996; 73:1145–1157.
4. Leroy K, Boutajangout A, Authelet M, Woodgett JR, Anderton BH, Brion JP. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease. Acta Neuropathol. 2002; 103:91–99.
5. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci USA. 2003; 100:10032–10037.
crossref
6. Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, LaFerla FM, Rohn TT, Cotman CW. Caspasecleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest. 2004; 114:121–130.
crossref
7. Lee HG, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, Takeda A, Nunomura A, Smith MA. Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol Med. 2005; 11:164–169.
crossref
8. Lee YJ, Kim NY, Suh YA, Lee C. Involvement of ROS in curcumin-induced autophagic cell death. Korean J Physiol Pharmacol. 2010; 15:1–7.
crossref
9. Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature. 2006; 443:780–786.
crossref
10. Todde V, Veenhuis M, van der Klei IJ. Autophagy: principles and significance in health and disease. Biochim Biophys Acta. 2009; 1792:3–13.
crossref
11. Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E, Tanaka K. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006; 441:880–884.
crossref
12. Cataldo AM, Hamilton DJ, Barnett JL, Paskevich PA, Nixon RA. Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease. J Neurosci. 1996; 16:186–199.
crossref
13. Nakamura Y, Takeda M, Suzuki H, Hattori H, Tada K, Hariguchi S, Hashimoto S, Nishimura T. Abnormal distribution of cathepsins in the brain of patients with Alzheimer's disease. Neurosci Lett. 1991; 130:195–198.
crossref
14. Ding H, Matthews TA, Johnson GV. Site-specific phosphorylation and caspase cleavage differentially impact tau-microtubule interactions and tau aggregation. J Biol Chem. 2006; 281:19107–19114.
crossref
15. Chun W, Johnson GV. Activation of glycogen synthase kinase 3beta promotes the intermolecular association of tau. The use of fluorescence resonance energy transfer microscopy. J Biol Chem. 2007; 282:23410–23417.
16. Cho JH, Johnson GV. Glycogen synthase kinase 3 beta induces caspase-cleaved tau aggregation in situ. J Biol Chem. 2004; 279:54716–54723.
17. Sun A, Nguyen XV, Bing G. Comparative analysis of an improved thioflavin-s stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections. J Histochem Cytochem. 2002; 50:463–472.
crossref
18. Wang Y, Martinez-Vicente M, Krüger U, Kaushik S, Wong E, Mandelkow EM, Cuervo AM, Mandelkow E. Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet. 2009; 18:4153–4170.
crossref
19. Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alphasynuclein. J Biol Chem. 2007; 282:5641–5652.
20. Chun W, Waldo GS, Johnson GV. Split GFP complementation assay: a novel approach to quantitatively measure aggregation of tau in situ: effects of GSK3beta activation and caspase 3 cleavage. J Neurochem. 2007; 103:2529–2539.
21. Sato S, Tatebayashi Y, Akagi T, Chui DH, Murayama M, Miyasaka T, Planel E, Tanemura K, Sun X, Hashikawa T, Yoshioka K, Ishiguro K, Takashima A. Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells. J Biol Chem. 2002; 277:42060–42065.
22. Kuret J, Chirita CN, Congdon EE, Kannanayakal T, Li G, Necula M, Yin H, Zhong Q. Pathways of tau fibrillization. Biochim Biophys Acta. 2005; 1739:167–178.
crossref
23. Feuillette S, Blard O, Lecourtois M, Frebourg T, Campion D, Dumanchin C. Tau is not normally degraded by the proteasome. J Neurosci Res. 2005; 80:400–405.
crossref
24. McCray BA, Taylor JP. The role of autophagy in age-related neurodegeneration. Neurosignals. 2008; 16:75–84.
crossref
25. Hamano T, Gendron TF, Causevic E, Yen SH, Lin WL, Isidoro C, Deture M, Ko LW. Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur J Neurosci. 2008; 27:1119–1130.
crossref
26. Rankin CA, Sun Q, Gamblin TC. Pseudo-phosphorylation of tau at Ser202 and Thr205 affects tau filament formation. Brain Res Mol Brain Res. 2005; 138:84–93.
crossref
27. Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow EM. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry. 1999; 38:3549–3558.
crossref
28. Poppek D, Keck S, Ermak G, Jung T, Stolzing A, Ullrich O, Davies KJ, Grune T. Phosphorylation inhibits turnover of the tau protein by the proteasome: influence of RCAN1 and oxidative stress. Biochem J. 2006; 400:511–520.
crossref
29. Alonso A, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci USA. 2001; 98:6923–6928.
30. Chun W, Johnson GV. The role of tau phosphorylation and cleavage in neuronal cell death. Front Biosci. 2007; 12:733–756.
crossref

Fig. 1.
Plasmid constructs of human tau. All types of human tau constructs are contained four microtubule-binding repeats but without exons 2 and 3. T4 is wild type of tau in pcDNA3.1(–). T4C3 is mimicking caspase-cleaved tau form which was deleted the last 20 amino acids at D421 in pcDNA3.1(+). Mutant constructs T4–2EC (S396E/S404E) is generated by mutating the serine 396 and 404 sites to glutamic acid to mimic phosphorylation.
kjpp-15-107f1.tif
Fig. 2.
Tau is degraded via the autophagic pathway. Representative immunoblot (A) and quantitative analysis (B) of intracellular tau levels. Tau constructs were transiently transfected into CHO cells. One day after transfection, 3-MA (5 mM) or trehalose (200 mM) was added to the medium immunobloted and incubated for 24 hrs. Lysates were immunobloted with tau (5A6), LC3, or β-actin antibodies. (B) The intensity of monomers and oligomers was quantitated by a densitometer and calculated as a fold to untreated control of each tau. Results are plotted as mean±SD from three independent experiments (n=3). 3-MA treatment caused the significant accumulation of oligomers in all tau species. Trehalose treatment exhibited decreased intracellular tau levels. Increased LC3-II levels indicate facilitated autophagic activity with trehalose treatment. Arrows indicate monomeric (∼50 kDa) and oligomeric (∼150 kDa) tau, respectively. p< 0.05, ∗∗p<0.01 to each control.
kjpp-15-107f2.tif
Fig. 3.
GSK3 β-phosphorylated T4 is less efficient in trehalose-facilitated autophagic degradation. (A) Representative immunoblots of tau levels with enzyme-inactive GSK3β (kinase-dead (k/D), left) or constitutively active GSK3β (S9A, right), respectively. Tau and each GSK3β constructs were transiently co-transfected into CHO cells. One day after transfection, 3-MA (5 mM) or trehalose (200 mM) was added to the medium and incubated for 24 hrs. Lysates were immunobloted with tau (5A6), LC3, GSK3β, or β-actin antibodies. (B) Quantitative analysis of tau levels. The intensity of monomers and oligomers was quantitated and calculated as a fold to untreated control of each tau. Results are plotted as mean±SD from three independent experiments (n=3). In the presence of kinase-dead GSK3β, 3-MA treatment resulted in the shift of monomeric tau to oligomeric tau in all tau species and trehalose treatment showed significantly decreased intracellular tau level of all tau species. In the presence of active GSK3β, 3-MA treatment resulted in the increased accumulation of oligomeric tau in all tau species. Trehalose treatment resulted in facilitated clearance of T4C3 and T4–2EC. However, phosphorylated T4 by GSK3β was not efficiently degraded, which indicates phosphorylation hinders autophagic degradation. LC3-II levels indicate facilitated autophagic activity with trehalose treatment. Arrows indicate monomeric (∼50 kDa) and oligomeric (∼150 kDa) tau, respectively. p<0.05, ∗∗p<0.01 to each control.
kjpp-15-107f3.tif
Fig. 4.
Activ me GSK3β and 3-MA treatment result in the formation of thioflavin-S-positive inclusions of tau in a co-operative manner. Each tau and active GSK3β or enzyme-inactive GSK3β constructs were transiently co-transfected into CHO cells on coverslips. One day after transfection, 3-MA (5 mM) or trehalose (200 mM) was added to the medium and incubated for 24 hrs. Cells fixed with 3% PFA were immunostained with an antibody that recognizes total tau (red) and counterstained with thioflavin-S (green). When tau and thioflavin-S staining co-localize, the merged image is yellow/orange. 3-MA treatment or active GSK3β exhibited thioflavin-S-positive tau inclusion in all tau species. Inhibition of autophagic activity and GSK3β-induced phosphorylation facilitated aggregate formation of tau in a co-operative manner. The scale bar shows 50 μm.
kjpp-15-107f4.tif
Fig. 5.
Co-operative facilitation of sarcosyl-insoluble aggregation with active GSK3β and 3-MA treatment. Cells were transiently transfected with each tau construct in the presence of constitutively active GSK3β or kinase-dead GSK3β. One day after transfection, the cells were treated with 3-MA for 24 hrs. Cell lysates were homogenized and then fractionated into RAB, RIRA, Sarkosyl-soluble, and Sarkosyl-insoluble fractions. After sarkosyl fractionation assay, each fraction was separated by SDS-PAGE and immunobloted with total tau antibody (5A6). Even in the absence of active GSK3β, partitioning into the sarkosyl-insoluble fraction was observed in T4C3, an aggregation-prone tau species, whereas not observed in T4 and T4–2EC. In the presence of active GSK3β, sarkosyl-insoluble aggregates were observed in all tau species and 3-MA treatment resulted in the increased amount of sarkosyl-insoluble aggregates.
kjpp-15-107f5.tif
TOOLS
Similar articles